# Clinical Trials Data KIT - Document 73

# The Oncopanel Pilot (TOP) Study

## Clinical Trial: https://clinicaltrials.gov/study/NCT02171286

"eligibilityCriteria": "Patients with archival tumor tissue and a known history of invasive malignancies are eligible if they meet one or more of the following criteria:\n\n\* Advanced colorectal cancer and eligible for standard KRAS testing,\n\* Advanced non-small cell lung cancer and eligible for standard EGFR testing,\n\* Advanced melanoma and eligible for standard BRAF testing,\n\* Gastrointestinal stromal tumors (GISTs) eligible for standard c-KIT and PDGFRA testing,\n\* Being considered for potential eligibility in clinical trial.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with advanced colorectal cancer, non-small cell lung cancer and melanoma and candidates for clinical trials.",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the clinical trial information provided, a patient with a KIT gene mutation could potentially be eligible for the trial, specifically under the category of gastrointestinal stromal tumors (GISTs). The eligibility criteria mention that patients with GISTs who are eligible for standard c-KIT and PDGFRA testing are included. Therefore, if the patient's mutation is related to GIST and involves the KIT gene, they would be eligible under this criteria.